XML 123 R111.htm IDEA: XBRL DOCUMENT v3.23.2
Supplemental Financial Information - Cash Flows (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Cash flows from operating activities          
Net income (loss) $ (62.7) $ 248.9 $ 62.6 $ 843.7  
Adjustments to reconcile net income to net cash flows from operating activities:          
Depreciation and amortization     88.1 59.9  
Equity-based compensation 68.0 45.4 122.4 85.1  
Non-cash performance allocations and incentive fees, net     298.7 (89.8)  
Other non-cash amounts     19.9 (11.9)  
Purchases of investments     (126.5) (456.8)  
Proceeds from the sale of investments     137.2 287.1  
Payments of contingent consideration     (68.6) (5.7)  
Changes in deferred taxes, net     (91.6) 55.9  
Change in due from affiliates and other receivables     (4.4) (65.3)  
Change in deposits and other     (49.0) (7.1)  
Change in accounts payable, accrued expenses and other liabilities     (39.7) (67.2)  
Change in accrued compensation and benefits     (201.6) (372.1)  
Change in due to affiliates     (8.4) 2.8  
Change in lease right-of-use assets and lease liabilities     (5.0) (4.6)  
Change in deferred revenue     5.0 (12.9)  
Net cash used in operating activities     (849.0) (558.5)  
Cash flows from investing activities          
Purchases of corporate treasury investments     (145.2) 0.0  
Proceeds from corporate treasury investments     122.4 0.0  
Purchases of fixed assets, net     (32.5) (17.4)  
Purchase of CBAM intangibles and investments, net     0.0 (618.4)  
Net cash used in investing activities     (55.3) (635.8)  
Cash flows from financing activities          
Payments on CLO borrowings     (4.5) (9.0)  
Proceeds from CLO borrowings, net of financing costs     0.0 41.1  
Dividends to common stockholders     (245.1) (207.1)  
Payment of deferred consideration for Carlyle Holdings units     (68.8) (68.8)  
Contributions from non-controlling interest holders     55.5 166.9  
Distributions to non-controlling interest holders     (34.1) (156.6)  
Common shares issued for performance allocations     0.0 36.5  
Common shares repurchased     (160.8) (105.3)  
Change in due to/from affiliates financing activities     (10.3) (27.7)  
Net cash provided by financing activities     408.0 75.9  
Effect of foreign exchange rate changes     10.5 (46.9)  
Decrease in cash, cash equivalents and restricted cash     (485.8) (1,165.3)  
Cash, cash equivalents and restricted cash, beginning of period     1,361.5 2,475.1  
Cash, cash equivalents and restricted cash, end of period 875.7 1,309.8 875.7 1,309.8  
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Cash and cash equivalents 870.3 1,308.9 870.3 1,308.9 $ 1,360.7
Restricted cash 5.4 0.9 5.4 0.9 0.8
Total cash, cash equivalents and restricted cash, end of period 875.7 1,309.8 875.7 1,309.8 1,361.5
Cash and cash equivalents held at Consolidated Funds 536.4 230.7 536.4 230.7 209.0
Consolidated Operating Entities          
Cash flows from operating activities          
Net income (loss)     14.3 814.0  
Adjustments to reconcile net income to net cash flows from operating activities:          
Depreciation and amortization     88.1 59.9  
Equity-based compensation     122.4 85.1  
Non-cash performance allocations and incentive fees, net     295.7 (94.6)  
Non-cash principal investment income     (0.2) (318.4)  
Other non-cash amounts     19.9 (11.9)  
Purchases of investments     (144.3) (470.3)  
Proceeds from the sale of investments     141.6 298.2  
Payments of contingent consideration     (68.6) (5.7)  
Changes in deferred taxes, net     (91.6) 55.9  
Change in due from affiliates and other receivables     (4.4) (64.8)  
Change in deposits and other     (49.0) (7.1)  
Change in accounts payable, accrued expenses and other liabilities     (39.7) (67.2)  
Change in accrued compensation and benefits     (201.6) (372.1)  
Change in due to affiliates     (8.4) 2.8  
Change in lease right-of-use assets and lease liabilities     (5.0) (4.6)  
Change in deferred revenue     5.0 (12.9)  
Net cash used in operating activities     74.2 (113.7)  
Cash flows from investing activities          
Purchases of corporate treasury investments     (145.2) 0.0  
Proceeds from corporate treasury investments     122.4 0.0  
Purchases of fixed assets, net     (32.5) (17.4)  
Purchase of CBAM intangibles and investments, net     0.0 (618.4)  
Net cash used in investing activities     (55.3) (635.8)  
Cash flows from financing activities          
Payments on CLO borrowings     (4.5) (9.0)  
Proceeds from CLO borrowings, net of financing costs     0.0 41.1  
Dividends to common stockholders     (245.1) (207.1)  
Payment of deferred consideration for Carlyle Holdings units     (68.8) (68.8)  
Contributions from non-controlling interest holders     5.2 4.4  
Distributions to non-controlling interest holders     (25.8) (36.6)  
Common shares issued for performance allocations     0.0 36.5  
Common shares repurchased     (160.8) (105.3)  
Change in due to/from affiliates financing activities     (13.2) (27.8)  
Net cash provided by financing activities     (513.0) (372.6)  
Effect of foreign exchange rate changes     8.3 (43.2)  
Decrease in cash, cash equivalents and restricted cash     (485.8) (1,165.3)  
Cash, cash equivalents and restricted cash, beginning of period     1,361.5 2,475.1  
Cash, cash equivalents and restricted cash, end of period 875.7 1,309.8 875.7 1,309.8  
Supplemental non-cash disclosures          
Issuance of common shares related to the acquisition of CBAM     0.0 194.5  
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Cash and cash equivalents 870.3 1,308.9 870.3 1,308.9  
Restricted cash 5.4 0.9 5.4 0.9  
Total cash, cash equivalents and restricted cash, end of period 875.7 1,309.8 875.7 1,309.8 $ 1,361.5
Cash and cash equivalents held at Consolidated Funds $ 536.4 $ 230.7 $ 536.4 $ 230.7